Beneficient Q1 revenue arrives at $12.2 million
Beneficient (NASDAQ:BENF) reported fiscal Q1 2027 GAAP revenue of $12.2 million and an operating loss of $0.4 million as expenses declined sharply.
Beneficient (NASDAQ:BENF) reported fiscal Q1 2027 GAAP revenue of $12.2 million and an operating loss of $0.4 million as expenses declined sharply.
MySize (NASDAQ:MYSZ) reported second-quarter revenue of $3.07 million, up 53% year over year, while net loss widened to $1.75 million.
Boost Run (NASDAQ:BRUN) reported Q2 revenue of $31.1 million, up 270%, while total long-term contracted revenue reached $1.9 billion.
SurgePays (NASDAQ:SURG) reported Q2 revenue of $16.2 million, up 40.7%, while net income available to common stockholders reached $1.29 million.
TuHURA Biosciences (NASDAQ:HURA) ended Q2 2026 with $1 million in cash as R&D spending rose to $6.6 million amid increased clinical activity.
LanzaTech (NASDAQ:LNZA) reported Q2 revenue of $9 million, down 1%, while operating expenses fell 67% to $11.7 million.
Lantern Pharma (NASDAQ:LTRN) reported a Q2 operating loss of $3.5 million, down 25%, while emerging LP-300 data showed 8.9-month median progression-free survival in selected patients.
Digi Power X (NASDAQ:DGXX) reported second-quarter revenue of approximately $6.6 million, including $1.1 million from its first AI GPU rental operations.
Mako Mining (NASDAQ:MAKO) reported record second-quarter revenue of $62.6 million, with adjusted EBITDA of $31.7 million and net income of $13.9 million.
Core Scientific (NASDAQ:CORZ) completed its $444 million cash acquisition of Polaris DS, securing approximately 440 MW of active grid-connected power capacity in Oklahoma.
GET YOUR GRAFA EDGE NOW
Sign up free to unlock this feature
We'll switch on a 30-day Edge trial as a welcome gift